Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02551159
Title Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

laryngeal squamous cell carcinoma

oropharynx cancer

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

Therapies

Cisplatin

Durvalumab

Carboplatin + Cetuximab + Fluorouracil

Tremelimumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.